Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

Jerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, Sushmita Datta, Paul O'Connor, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Philippe Truffinet, Lin Wang, Aaron Miller, Mark S Freedman, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group, Egon Stenager (Medlem af forfattergruppering)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI).
OriginalsprogEngelsk
TidsskriftMultiple sclerosis
Vol/bind19
Udgave nummer10
Sider (fra-til)1310-19
Antal sider10
ISSN1352-4585
DOI
StatusUdgivet - 2013

    Fingerprint

Bibliografisk note

Prefessor Egon Stenager er medlem af TEMSO-gruppen

Citationsformater

Wolinsky, J. S., Narayana, P. A., Nelson, F., Datta, S., O'Connor, P., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Truffinet, P., Wang, L., Miller, A., Freedman, M. S., Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group, & Stenager, E. (2013). Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Multiple sclerosis, 19(10), 1310-19. https://doi.org/10.1177/1352458513475723